MARCKS and B-cell chronic lymphocytic leukemia: Next, we utilized the validation patient groups (NMCL=6, NCLL=8; Supplementary Tables S9 and S10) to study MARCKS expression at protein levels by flow cytometry and confirmed that MCL cells expressed significantly higher level of MARCKS compared with CLL samples (Supplementary Figure S3b).